Cargando…

Evaluation of the Lung Immune Prognostic Index in Non-Small Cell Lung Cancer Patients Treated With Systemic Therapy: A Retrospective Study and Meta-Analysis

The lung immune prognostic index (LIPI) has been shown to be an important prognostic marker for various tumors. However, the prognostic value of LIPI among non-small cell lung cancer (NSCLC) patients treated with systemic therapy remains controversial. We aimed to evaluate survival status according...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Litang, Han, Hedong, Zhou, Li, Chen, Xi, Xu, Qiuli, Xie, Jingyuan, Zhan, Ping, Chen, Si, Lv, Tangfeng, Song, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264771/ https://www.ncbi.nlm.nih.gov/pubmed/34249708 http://dx.doi.org/10.3389/fonc.2021.670230

Ejemplares similares

Association of MUC19 Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer
por: Zhou, Li, et al.
Publicado: (2021)

The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Xu, Yangyang, et al.
Publicado: (2021)

Serum Exosomal miRNA Might Be a Novel Liquid Biopsy to Identify Leptomeningeal Metastasis in Non-Small Cell Lung Cancer
por: Xu, Qiuli, et al.
Publicado: (2021)

Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer
por: Xu, Yangyang, et al.
Publicado: (2022)

Clinical impact of first‐line PD‐1 or PD‐L1 inhibitors combined with chemotherapy in extensive‐stage small cell lung cancer patients: A real‐world multicenter propensity score‐matched study
por: Xie, Jingyuan, et al.
Publicado: (2023)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Efficacy of different therapies for brain metastases of non-small cell lung cancer: a systematic review and meta-analysis
por: Chen, Mo, et al.
Publicado: (2023)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
por: Wang, Donghui, et al.
Publicado: (2021)

The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index
por: Zhang, Ting, et al.
Publicado: (2021)

Safety and efficacy of thoracic radiotherapy combined with chemo-immunotherapy in patients with extensive-stage small cell lung cancer: a multicenter retrospective analysis
por: Cai, Zijing, et al.
Publicado: (2023)

Combined systemic immune-inflammatory index and prognostic nutritional index predict outcomes in advanced non-small cell lung cancer patients receiving platinum-doublet chemotherapy
por: Fan, Ruiyun, et al.
Publicado: (2023)

Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy
por: Li, Lingling, et al.
Publicado: (2021)

Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis
por: Li, Huijuan, et al.
Publicado: (2023)

Assessment of Naples prognostic score in predicting survival for small cell lung cancer patients treated with chemoradiotherapy
por: Liu, Jiafeng, et al.
Publicado: (2023)

Prognostic Significance of the Systemic Immune-Inflammation Index (SII) in Patients With Small Cell Lung Cancer: A Meta-Analysis
por: Zhou, Yuting, et al.
Publicado: (2022)

Association between absolute volumes of lung spared from low-dose irradiation and radiation-induced lung injury after intensity-modulated radiotherapy in lung cancer: a retrospective analysis
por: Chen, Jinmei, et al.
Publicado: (2015)

Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis
por: Cai, Zijing, et al.
Publicado: (2022)

Over-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer
por: Lv, Tangfeng, et al.
Publicado: (2012)

Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer
por: Diker, Omer, et al.
Publicado: (2023)

Editorial: Prognostic factors in non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2023)

Evaluation of Predictive and Prognostic Importance of Lung Immune Prognostic Index in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy
por: Arıkan, Rukiye, et al.
Publicado: (2023)

Identification of non-small cell lung cancer with chronic obstructive pulmonary disease using clinical symptoms and routine examination: a retrospective study
por: Zhuan, Bing, et al.
Publicado: (2023)

A New Prognostic Index Combines the Metabolic Response and RECIST 1.1 to Evaluate the Therapeutic Response in Patients With Non-Small Cell Lung Cancer
por: Tang, Wenfang, et al.
Publicado: (2020)

Novel Diagnostic and Prognostic Tools for Lung Cancer Cachexia: Based on Nutritional and Inflammatory Status
por: Liu, Chen-An, et al.
Publicado: (2022)

Identification of Prognostic Model Based on Immune-Related LncRNAs in Stage I-III Non-Small Cell Lung Cancer
por: Li, Qiaxuan, et al.
Publicado: (2021)

Risk factors for symptomatic malignant pleural effusion recurrence in patients with actionable mutations in advanced lung adenocarcinoma
por: Xu, Ke, et al.
Publicado: (2023)

Prognostic Value of the Geriatric Nutritional Risk Index in Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis
por: Wang, Haoyu, et al.
Publicado: (2022)

Small Cell Size Circulating Aneuploid Cells as a Biomarker of Prognosis in Resectable Non-Small Cell Lung Cancer
por: Hong, Yang, et al.
Publicado: (2021)

Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer
por: Sun, Bochen, et al.
Publicado: (2022)

Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study
por: Chen, Zhe, et al.
Publicado: (2021)

Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study
por: Shangguan, Jian, et al.
Publicado: (2023)

Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer
por: Peng, Muyun, et al.
Publicado: (2020)

The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer
por: Matsuura, Shun, et al.
Publicado: (2023)

Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study
por: Song, Zhengbo, et al.
Publicado: (2021)

Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection
por: Shen, Yu-Jia, et al.
Publicado: (2021)

Development of RECLS score to predict survival in lung cancer patients with malignant pleural effusion
por: Zhang, Tianli, et al.
Publicado: (2021)

Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases
por: Liu, Hao, et al.
Publicado: (2022)

Identification of a Prognostic Model Based on Immune-Related Genes of Lung Squamous Cell Carcinoma
por: Li, Rui, et al.
Publicado: (2020)

Pyroptosis: A new insight of non-small-cell lung cancer treatment
por: Chen, Xi, et al.
Publicado: (2022)

Development of a Survival Prognostic Model for Non-small Cell Lung Cancer
por: Zhang, Yue-Hua, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2snhcru507rudutti6ovkkefmu